HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CIR's Draft Review Priorities Reflect International Activity, NGO Targets

This article was originally published in The Rose Sheet

Executive Summary

The Cosmetic Ingredient Review Expert Panel is set to finalize its list of ingredient priorities for review in 2017 at its June 6-7 meeting in Washington.

You may also be interested in...



CIR Panel Plans For Lead Acetate Review At FDA’s Request

While FDA has gone on record as being leery of proposed legislation that would formalize its relationship with the Cosmetic Ingredient Review, the agency continues to leverage the industry-funded program’s expertise. At FDA’s request, the CIR Expert Panel will review progressive hair dye lead acetate in 2017.

CIR Panel Prioritizes Paraben Review To Signal EU Before It's 'Too Late'

At their March 31-April 1 meeting, CIR's experts opted to tentatively prioritize sodium methylparaben for review in 2017, which could allow them to make a statement on paraben safety in general as regulatory movement in the EU continues to put the ingredients' use in jeopardy.

Rep. Pallone Readying Cosmetics Bill Following EWG Nail Ingredient Study

A new study from the Environmental Working Group and Duke University links common nail polish ingredient triphenyl phosphate to elevated levels in user's blood of a metabolite suspected of endocrine disruption. The Personal Care Products Council calls the study "speculative" and "misleading," while Rep. Frank Pallone, D-N.J., says its results signal a need for new legislation to update cosmetics regulations.

Topics

UsernamePublicRestriction

Register

RS019925

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel